Anti- anginal drugs.

Slides:



Advertisements
Similar presentations
MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE FEBRUARY 10,2110.
Advertisements

CASE 21 Michelle Legaspi. 65 y/o male retired teacher sought consult because of occasional chest heaviness non-radiating occuring during a moderate physical.
Coronary vasodilators Antianginal drugs  Angina pectoris: is a clinical syndrome characterized by paroxysm of pain in the anterior chest caused by insufficient.
Drugs to treat angina. I. Introduction Branching off the aorta are the coronary arteries.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 51 Drugs for Angina Pectoris.
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm. Due to imbalance between myocardium oxygen requirement and.
Ischemic heart disease
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 45 Calcium Channel Blockers.
Calcium Channel Blocking Drugs.
Spasm/obstruction of coronary arteriesMyocardial ischemiaReduced O2 supply to myocardium Chest pain---Angina pectoris Angina pectoris Chest pain due to.
Angina Pectoris “Chest pain” or angina pectoris is a symptom of ischemic heart disease caused by an imbalance between oxygen requirement of the heart and.
Calcium Antagonists Tatyana Voyno-Yasenetskaya
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Chapter 18 Agents that Dilate Blood Vessels. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Coronary.
EMS 353. Lectures 6 Dr. Maha Khalid physiology of pharmacology cardiovascular system.
Cardio pharmacology Angina. angina Causes Atheroma Others: Aortic stenosis, aberrant coronary circulation, severe anaemia, arteritis Prevention Decrease.
1 ANGINA ANGINA MYOCARDIAL OXY. DEMAND >. OXY. SUPPLY. OXY. SUPPLY < SYMPTOMS – chest pain mostly relieved by taking rest, dyspnea, sweating, nausea..
MAIN EXIT NEXT Definition Types of Angina Management of Angina Antianginal drugs BY: DR. MARWA SHAALAN.
Drugs in the Therapy of Angina Dr. Thomas Abraham PHAR417: Fall 2004.
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
Drug Therapy Heart Failure by Pat Woodbery, MSN, ARNP.
Agents that Dilate Coronary Blood Vessels.  Coronary artery disease (CAD) results from atherosclerosis  Clinical symptoms caused by  narrowing of the.
Antianginal Drugs Learning outcomes Recognize variables contributing to a balanced myocardial supply versus demand Expand on the drugs used to alleviate.
Drug Treatment of Ischemic Heart Disease Fixed "Stable" Angina Variant Angina Unstable Angina Myocardial Infarction.
BIMM118 Angina pectoris Medical term for chest pain or discomfort due to coronary heart disease. Typical angina pectoris (=“tight heart” is uncomfortable.
for more lecture notes Antianginal Agents Dr.Shadi-Sarahroodi Pharm.D & PhD Qom University of Medical sciences Iran PUBLISHED.
They bind to the channel from the inner side of the membrane. They bind to channels in depolarized membranes. Binding  ↓ frequency of opening of the channels.
Antianginal drugs Angina pectoris is the severe chest pain that occurs when coronary blood flow is inadequate to supply the oxygen required by the heart.
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm. Due to imbalance between myocardium oxygen requirement and.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 46 Vasodilators.
Ischemic heart diseases Ischemia : it is inadequate supply of O2 to an organ or tissue (result from inadequate blood flow) insufficient to meet the organ’s.
Therapeutics for Coronary Vascular Disease Nitrates.
Drugs used in angina pectoris
Angina pectoris Sudden, severe, pressing chest pain and radiating to the neck, jaw, back, and arms. The episodes are transient, stay between 15 sec to.
- Calcium channel blockers decrease blood pressure,cardiac workload, and myocardial oxygen consumption. - available in immediate-release and sustained-release.
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Antianginal drugs Antidysrrhytmic drugs
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm & neck. Due to imbalance between myocardium oxygen requirement.
Anti-anginal Drugs Angina pectoris is a characteristic sudden severe pressing chest pain or heaviness radiating to the neck, jaw, back and arms. It is.
ANTIANGINAL AGENTS. Atherosclerotic disease of the coronary arteries, also known as coronary artery disease or ischemic heart disease, is the most common.
MCQs framed from High yield areas of Anti-anginal Pharmacology
Antianginal (Anti-ischaemic) Drugs
Myocardial Infarction Angina Pectoris What is an MI?
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.1 Drugs for Angina Pectoris.
Drugs for Angina Pectoris
Adrenergic Antagonists
PHARMACOLOGY OF ANTI-ANGINAL DRUGS (ID#580) Dr. Mariam Yousif Pharmacology & Toxicology Dept. November 17 th, 2014.
Calcium Channel Blocking Drugs.
Drug Therapy of Angina Pectoris
Antianginal Drugs Learning outcomes
Anti-Anginal Drugs.
Antianginal Drugs Learning outcomes
Formative Test.
Anti-Anginal Agents Angina Disease, symptoms
New Paradigm of Anti Anginal Therapy dr.Yerizal Karani SpPD,SpJP(K)
Anti Anginal Agents Pharmacology Week 10.
ANTI-ANGINAL DRUGS February 2017.
Anti-Anginal Drugs.
ANTI HYPERTENSIVE DRUGS
NITRATES 20/01/2011.
Treatment of Angina Pectoris [æn‘dʒaɪnə] [’pektəris] 心绞痛治疗
ORGANIC NITRATES February 2017.
Antianginal Drugs.
Anti hypertensive Drugs
Antianginal Drugs Ass. Prof. Naza M. Ali Lec 3-4 G2 21 April 2019
Drugs Used to Treat Angina Pectoris
Antianginal Drugs Learning outcomes
Anti Anginal Agents Pharmacology Week 10.
Chaper 20 Adrenoceptor Antagonists
Presentation transcript:

Anti- anginal drugs

content Anti anginal drugs Angina pectoris Types Classification Nitrates Calcium channel blockers b blockers Combination therapy content

Anti-anginal drugs Antianginal drugs may relieve attacks of acute myocardial ischemia by increasing myocardial oxygen supply or by decreasing myocardial oxygen demand Three groups of pharmacological agents have been shown to be effective in reducing the frequency, severity, or both of primary or secondary angina. These agents include the nitrates, adrenoceptor antagonists, and calcium entry blockers. To understand the beneficial actions of these agents, it is important to be familiar with the major factors regulating the balance between myocardial oxygen supply and demand.

Angina pectoris It is the principal symptoms of patient with ischemic heart disease. Manifested by sudden, severe, pressing substernal pain that often radiates to the left shoulder and along the flexor surface of the left arm. Usually precipitated by exercise, excitement or a heavy meal.

Types of angina pectoris

nitrates Classification of nitrates: Rapidly acting nitrates * used to terminate acute attack of angina * e.g.- Nitroglycerin and Amyl nitrate * usually administered sublingually Long acting nitrates * used to prevent an attack of angina * e.g. – tetra nitrate, Iso sorbide di nitrate, Penta erythrytol tetra nitrate * administered orally or topically

Organic nitrates & nitrites are simple nitric & nitrous esters of glycerol. These agents cause a rapid decrease in myocardial oxygen demand leading to rapid resolution of symptoms. Nitrates are effective for all types of angina. Activation of guanylate cyclase increases cGMP activating a cGMP kinase leading to dephosphorylation of myosin light chains decreasing contractile force. Organic nitrates

1st mechanism of action Coronary artery dilatation Decrease coronary bed resistance (Relieved coronary vasospasm) Increase coronary blood flow Increase oxygen supply

2nd mechanism of action Reduction on peripheral resistance (Secondary to dilatation of aorta) Decrease blood pressure Decrease after load Decrease workload Decrease oxygen consumption

3rd mechanism of action Reduced venous return (Due to dilatation of the veins) Decrease left ventricular volume Decrease preload Decrease workload Decrease oxygen consumption

Route of administration 1. Sublingual route – rational and effective for the treatment of acute attacks of angina pectoris. Half-life depend only on the rate at which they are delivered to the liver. 2. Oral route – to provide convenient and prolonged prophylaxis against attacks of angina 3. Intravenous Route – useful in the treatment of coronary vasospasm and acute ischemic syndrome. 4. Topical route – used to provide gradual absorption of the drug for prolonged prophylactic purpose.

Route of administration Duration of action Drug Usual single dose Route of administration Duration of action Short acting Nitroglycerin 0.15-1.2 mg sublingual 10 - 30 min Isosorbide dinitrate 2.5-5 mg 10 – 60 min Amyl nitrite 0.18 – 3 ml inhalation 3 – 5 min Long acting Nitroglycerin sustained action 6.5 – 13 mg q 6-8 hrs oral 6 – 8 hrs Nitroglycerin 2% ointment 1 – 1.5 inches q hr topical 3 – 6 hrs Niroglycerin slow released 1 –2 mg per 4 hrs Buccal mucosa Nitroglycerin slow released 10 – 25 mg /24hrs (one patch/day} transdermal 8 –10 hrs 2.5 – 10 mg per 2 hrs 1.5 – 2 hrs 10 –60 mg per 4-6 hrs 4 – 6 hrs Isosorbide dinitrate chewable 5 – 10 mg per 2-4 hrs 2 – 3 hrs Isosorbide mononitrate 20 mg per 12 hrs 6 –10 hrs

effects 1. Coronary artery dilatation 2. Reduction of peripheral arterial resistance – decrease after load 3. Reduce venous return – decrease preload

pharmacokinetics The difference between nitrate preparations is mainly in time of onset of action. Nitroglycerin suffers marked 1st pass metabolism so administration is sublingual. t1/2 ~10 minutes. Occasionally as nitroglycerin is metabolized anginal symptoms will return. Transdermal administration either as patch or paste provides a depot of agent for a steady availability. Nitro-Bid is an oral or topical preparation which saturates the hepatic catabolic pathways allowing a prolonged level of nitroglycerine. Isosorbide mono nitrate & Isosorbide di nitrate are long acting nitrates that are relatively resistant to hepatic catabolism ……t1/2 ~ 1 hour.

Adverse effects 1. Throbbing headache 2. Flushing of the face 3. Dizziness – especially at the beginning of treatment 4. Postural Hypotension – due to pooling of blood in the dependent portion of the body

contraindications 1. Renal ischemia 2. Acute myocardial infarction 3. Patients receiving other antihypertensive agent

Beta- blockers β-Blockers decrease oxygen demands of the myocardium by lowering the heart rate and contractility (decrease CO) particularly the increased demand associated with exercise. They also reduce PVR by direct vasodilatations of both arterial & venous vessels reducing both pre- and after load. These effects are caused by blocking β1 receptors, selective β1 antagonists (atenolol, metoprolol ) lose their selectivity at high doses and at least partially block β2 receptors.

β1 antagonists reduce the frequency and severity of anginal episodes particularly when used in combination with nitrates. β1 antagonists have been shown to improve survival in post MI patients and decrease the risk of subsequent cardiac events & complications. There are a number of contraindications for β blockers: asthma, diabetes, bradycardia, PVD & COPD. β-Blockers in combination with nitrates can be quite effective

Hemodynamic effect 1. Decrease heart rate 2. Reduced blood pressure and cardiac contractility without appreciable decrease in cardiac output

Decrease heart rate & Contractility Mechanism of action Decrease heart rate & Contractility Increase duration of diastole Decrease workload Increase coronary blood flow Decrease oxy.consumption Increase oxygen supply

contraindications 1. Congestive heart failure 2. Asthma 3. Complete heart block

Calcium channel blockers Ca+2 channel blockers protect tissue by inhibiting the entrance of Ca+2 into cardiac and smooth muscle cells of the coronary and systemic arterial beds. All Ca+2 channel blockers produce some vasodilation (↓ PVR) and (-) inotropes. Some agents also show cardiac conduction particularly through the AV node thus serving to control cardiac rhythm. Some agents have more effect on cardiac muscle than others but all serve to lower blood pressure. CHF patients may suffer exacerbation of their failure as these are (-) inotropes. They are useful in Prinzmetal angina in conjunction with nitrates.

agents Nifedipine: This Ca+2 channel blocker works mainly on the arteriolar vasculature decreasing after load it has minimal effect of conduction or HR. It is metabolized in the liver and excreted in both the urine & the feces. It causes flushing, headache, hypotension and peripheral edema. It also has some slowing effect on the GI musculature resulting in constipation. A reflex tachycardia associated with the vasodilatation may elicit myocardial ischemia in tenuous patients, as such it is generally avoided in non-hypertensive coronary artery disease.

verapamil The agents has its main effect on cardiac conduction decreasing HR and thereby O2 demand. It also has much more (-) inotropic effect than other Ca+2 channel blockers It is a weak vasodilator. Because of its focused myocardial effects it is not used as an antianginal unless there is a tachyarrhythmia. It is metabolized in the liver. It interferes with digoxin levels causing elevated plasma levels; caution and monitoring of drug levels are necessary wit concomitant use.

diltiazem This agent function similarly to Verapamil however it is more effective against Prinzmetal angina. It has less effect on HR. It has similar metabolism and side effects as Verapamil.

pharmacokinetics Drugs Onset of action Peak of action Half-life Nifedipine 20 minutes 1 hour 3-4 hours Verafamil 1-2 hours 5 hours 8-10 hours Diltiazem 15 minutes 30 minutes Nicardifine 45 minutes 2-4 hours Felodipine 2-5 hours 6-7 hours 11-16 hour

Adverse effect Nausea and vomiting Dizziness Flushing of the face Tachycardia – due to hypotension

contraindications Cardiogenic shock Recent myocardial infarction Heart failure Atria-ventricular block

1. Nitrates and B-blockers Combination therapy 1. Nitrates and B-blockers The additive efficacy is primarily a result of one drug blocking the adverse effect of the other agent on net myocardial oxygen consumption B-blockers – blocks the reflex tachycardia associated with nitrates Nitrates – attenuate the increase in the left ventricular end diastolic volume associated with B-lockers by increasing venous capacitance

Calcium channel blockers +beta blockers Useful in the treatment of exertional angina that is not controlled adequately with nitrates and B-blockers B-blockers – attenuate reflex tachycardia produce by nifedipine These two drugs produce decrease blood pressure

Calcium channel blocker+nitrates Useful in severe vasospastic or exertional angina (particularly in patient with exertional angina with congestive heart failure and sick sinus syndrome) Nitrates reduce preload and after load Ca channels reduces the after load Net effect is on reduction of oxygen demand

Triple drugs:-nitrates+calcium channel blockers+beta blocker Useful in patients with exertional angina not controlled by the administration of two types of anti-anginal agent Nifidipine – decrease after load Nitrates – decrease preload B-blockers – decrease heart rate & myocardial contractility

Anjali kotwal 5th semester b.pharmacy shoolini university Presented by: Anjali kotwal 5th semester b.pharmacy shoolini university